Histo-Scientific Research Laboratories and Vet Path Services Merge

December 14, 2018
Pharmaceutical Technology Editors

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletter, Pharmaceutical Technology\'s In the Lab eNewsletter-01-09-2019, Volume 14, Issue 1

The merged companies will provide histopathology services in the research and pre-clinical therapeutics markets.

Histo-Scientific Research Laboratories (HSRL), a histology and pathology services provider based in Mount Jackson, VA, announced on Dec. 11, 2018 that it completed its merger with contract histopathology company Vet Path Services (VPS) to provide research and pre-clinical histology, pathology, and archiving services for the biopharmaceutical, medical device, and contract research industries.  

HSRL specializes in histology and pathology services for routine tissue analyses, efficacy determination for new compounds and devices, toxicologic evaluation of products subject to FDA approval, and detailed pathology reporting for good laboratory practices (GLP) studies in the pre-clinical research and development market. VPS offers substantially corresponding histology and pathology expertise that will play a valuable role in growing the combined company’s service capabilities. With the merger, the organization now has footprints in Mount Jackson, VA; Mason, OH; and Worcester, MA.  The company plans to significantly expand its Worcester site, where complex immunohistochemical techniques and image analysis is performed, in order to serve demand for these services in the market. 

“We are very excited to partner with VPS to expand HSRL’s service offerings, and to rapidly scale the combined company to meet the growing demand for high-quality histopathology services in the research and pre-clinical therapeutics markets,” stated Mr. Thomas Galati, founder and CEO of HSRL, who will serve as CEO of the combined entity, in a company press release. “The addition of VPS brings not only valuable technical and operational expertise, but also increased service capabilities and a specialized comprehension of complex histopathology with regard to medical devices.”  

“Our partnership with HSRL represents a highly complementary union of histology and pathology expertise that is unrivaled in the industry,” said founder and vice president of VPS, Chris Johnson, in the release. “The combination creates an organization that has access to over 25 board-certified veterinary pathologists, who together offer a diverse experience base and the scientific ability to accomplish any project.” 

In conjunction with the merger, the new company has received an investment from Ampersand Capital Partners, a leading private equity fund focused on the healthcare sector.

Source: Ampersand Capital Partners